NR4A1 and breast carcinoma: The results from the TROPION-PanTumor01 study show a progression-free survival (PFS) HR of 0.63 (P < 0.0001) and a trend in overall survival (OS) with a HR of 0.84 for patients that received Dato-DXd compared with eribulin/vinorelbine/capecitabine/gemcitabine with hormone receptor–positive breast cancer and HER2-negative breast cancer (22).